BCYC
Closed
Bicycle Therapeutics Ltd
7.03
+0.08 (+1.15%)
Last Update: 01 Jul 2025 23:00:00
Yesterday: 6.95
Day's Range: 6.87 - 7.23
Send
sign up or login to leave a comment!
When Written:
21.27
Bicycle Therapeutics Ltd is a clinical-stage biopharmaceutical company that focuses on the development of innovative treatments for cancer and other diseases. The company was founded in 2009 and is headquartered in Cambridge, United Kingdom.
Bicycle Therapeutics' technology platform is based on the use of bicyclic peptides, which are small, highly stable molecules that can be engineered to target specific disease targets. These peptides can be designed to have high affinity and specificity for a particular target, while also being able to penetrate into cells and tissues.
The company's lead product candidate, BT1718, is a bicyclic peptide-drug conjugate that targets MT1-MMP, a protein that is overexpressed in many solid tumors. BT1718 is currently being evaluated in a phase 1/2a clinical trial for the treatment of advanced solid tumors.
Bicycle Therapeutics has also developed a pipeline of other bicyclic peptide-based product candidates for the treatment of cancer and other diseases, including inflammatory disorders and respiratory diseases.
The company has collaborations with several pharmaceutical companies, including AstraZeneca, Oxurion, and Bioverativ, to develop and commercialize its product candidates.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Bicycle Therapeutics' technology platform is based on the use of bicyclic peptides, which are small, highly stable molecules that can be engineered to target specific disease targets. These peptides can be designed to have high affinity and specificity for a particular target, while also being able to penetrate into cells and tissues.
The company's lead product candidate, BT1718, is a bicyclic peptide-drug conjugate that targets MT1-MMP, a protein that is overexpressed in many solid tumors. BT1718 is currently being evaluated in a phase 1/2a clinical trial for the treatment of advanced solid tumors.
Bicycle Therapeutics has also developed a pipeline of other bicyclic peptide-based product candidates for the treatment of cancer and other diseases, including inflammatory disorders and respiratory diseases.
The company has collaborations with several pharmaceutical companies, including AstraZeneca, Oxurion, and Bioverativ, to develop and commercialize its product candidates.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!